Global Sustained Release Injectables Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Sustained Release Injectables market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Sustained Release Injectables market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Sustained Release Injectables market include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Sustained Release Injectables, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Sustained Release Injectables, also provides the value of main regions and countries. Of the upcoming market potential for Sustained Release Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sustained Release Injectables revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Sustained Release Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Sustained Release Injectables company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Sustained Release Injectables Segment by Company
Sanofi
Novartis
Merck
Luye Pharma Group
Roche
Livzon Pharm
Eli Lilly
AstraZeneca
Xbrane Biopharma
Taiwan Liposome Company (TLC)
Recipharm AB
PhaseBio Pharmaceuticals
Pacira
OctoPlus
Oakwood Laboratories/PharmaSophia
NanOlogy
Janssen
Ipsen
InnoCore Pharmaceuticals
Enzon
Durect
Critical Pharmaceuticals
Camurus
Biomarin
Avadel
Aurobindo
Ascendis Pharma
AntriaBio
Amylin Pharmaceuticals
Alkermes
Sustained Release Injectables Segment by Type
Gels
Microparticles
Implants
Sustained Release Injectables Segment by Application
Oncology
CNS
Acromegaly
Ophthalmology
Diabetes
Reproductive Health
Rheumatology
Leukemia
Others
Sustained Release Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Sustained Release Injectables status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Sustained Release Injectables key companies, revenue, market share, and recent developments.
3. To split the Sustained Release Injectables breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Sustained Release Injectables market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Sustained Release Injectables significant trends, drivers, influence factors in global and regions.
6. To analyze Sustained Release Injectables competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sustained Release Injectables industry.
Chapter 3: Detailed analysis of Sustained Release Injectables company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Sustained Release Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Sustained Release Injectables in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Sustained Release Injectables market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Sustained Release Injectables market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Sustained Release Injectables market include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Sustained Release Injectables, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Sustained Release Injectables, also provides the value of main regions and countries. Of the upcoming market potential for Sustained Release Injectables, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sustained Release Injectables revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Sustained Release Injectables market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Sustained Release Injectables company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Sustained Release Injectables Segment by Company
Sanofi
Novartis
Merck
Luye Pharma Group
Roche
Livzon Pharm
Eli Lilly
AstraZeneca
Xbrane Biopharma
Taiwan Liposome Company (TLC)
Recipharm AB
PhaseBio Pharmaceuticals
Pacira
OctoPlus
Oakwood Laboratories/PharmaSophia
NanOlogy
Janssen
Ipsen
InnoCore Pharmaceuticals
Enzon
Durect
Critical Pharmaceuticals
Camurus
Biomarin
Avadel
Aurobindo
Ascendis Pharma
AntriaBio
Amylin Pharmaceuticals
Alkermes
Sustained Release Injectables Segment by Type
Gels
Microparticles
Implants
Sustained Release Injectables Segment by Application
Oncology
CNS
Acromegaly
Ophthalmology
Diabetes
Reproductive Health
Rheumatology
Leukemia
Others
Sustained Release Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Sustained Release Injectables status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Sustained Release Injectables key companies, revenue, market share, and recent developments.
3. To split the Sustained Release Injectables breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Sustained Release Injectables market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Sustained Release Injectables significant trends, drivers, influence factors in global and regions.
6. To analyze Sustained Release Injectables competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sustained Release Injectables industry.
Chapter 3: Detailed analysis of Sustained Release Injectables company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Sustained Release Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Sustained Release Injectables in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
214 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Sustained Release Injectables Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Sustained Release Injectables Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Sustained Release Injectables Market Dynamics
- 2.1 Sustained Release Injectables Industry Trends
- 2.2 Sustained Release Injectables Industry Drivers
- 2.3 Sustained Release Injectables Industry Opportunities and Challenges
- 2.4 Sustained Release Injectables Industry Restraints
- 3 Sustained Release Injectables Market by Company
- 3.1 Global Sustained Release Injectables Company Revenue Ranking in 2024
- 3.2 Global Sustained Release Injectables Revenue by Company (2020-2025)
- 3.3 Global Sustained Release Injectables Company Ranking (2023-2025)
- 3.4 Global Sustained Release Injectables Company Manufacturing Base and Headquarters
- 3.5 Global Sustained Release Injectables Company Product Type and Application
- 3.6 Global Sustained Release Injectables Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Sustained Release Injectables Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Sustained Release Injectables Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Sustained Release Injectables Market by Type
- 4.1 Sustained Release Injectables Type Introduction
- 4.1.1 Gels
- 4.1.2 Microparticles
- 4.1.3 Implants
- 4.2 Global Sustained Release Injectables Sales Value by Type
- 4.2.1 Global Sustained Release Injectables Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Sustained Release Injectables Sales Value by Type (2020-2031)
- 4.2.3 Global Sustained Release Injectables Sales Value Share by Type (2020-2031)
- 5 Sustained Release Injectables Market by Application
- 5.1 Sustained Release Injectables Application Introduction
- 5.1.1 Oncology
- 5.1.2 CNS
- 5.1.3 Acromegaly
- 5.1.4 Ophthalmology
- 5.1.5 Diabetes
- 5.1.6 Reproductive Health
- 5.1.7 Rheumatology
- 5.1.8 Leukemia
- 5.1.9 Others
- 5.2 Global Sustained Release Injectables Sales Value by Application
- 5.2.1 Global Sustained Release Injectables Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Sustained Release Injectables Sales Value by Application (2020-2031)
- 5.2.3 Global Sustained Release Injectables Sales Value Share by Application (2020-2031)
- 6 Sustained Release Injectables Regional Value Analysis
- 6.1 Global Sustained Release Injectables Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Sustained Release Injectables Sales Value by Region (2020-2031)
- 6.2.1 Global Sustained Release Injectables Sales Value by Region: 2020-2025
- 6.2.2 Global Sustained Release Injectables Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Sustained Release Injectables Sales Value (2020-2031)
- 6.3.2 North America Sustained Release Injectables Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Sustained Release Injectables Sales Value (2020-2031)
- 6.4.2 Europe Sustained Release Injectables Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Sustained Release Injectables Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Sustained Release Injectables Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Sustained Release Injectables Sales Value (2020-2031)
- 6.6.2 South America Sustained Release Injectables Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Sustained Release Injectables Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Sustained Release Injectables Sales Value Share by Country, 2024 VS 2031
- 7 Sustained Release Injectables Country-level Value Analysis
- 7.1 Global Sustained Release Injectables Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Sustained Release Injectables Sales Value by Country (2020-2031)
- 7.2.1 Global Sustained Release Injectables Sales Value by Country (2020-2025)
- 7.2.2 Global Sustained Release Injectables Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.7.2 France Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.14.2 China Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.17.2 India Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Sustained Release Injectables Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Sustained Release Injectables Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Sustained Release Injectables Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Comapny Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.1.4 Sanofi Sustained Release Injectables Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Comapny Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.2.4 Novartis Sustained Release Injectables Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Merck
- 8.3.1 Merck Comapny Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.3.4 Merck Sustained Release Injectables Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Luye Pharma Group
- 8.4.1 Luye Pharma Group Comapny Information
- 8.4.2 Luye Pharma Group Business Overview
- 8.4.3 Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
- 8.4.5 Luye Pharma Group Recent Developments
- 8.5 Roche
- 8.5.1 Roche Comapny Information
- 8.5.2 Roche Business Overview
- 8.5.3 Roche Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.5.4 Roche Sustained Release Injectables Product Portfolio
- 8.5.5 Roche Recent Developments
- 8.6 Livzon Pharm
- 8.6.1 Livzon Pharm Comapny Information
- 8.6.2 Livzon Pharm Business Overview
- 8.6.3 Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
- 8.6.5 Livzon Pharm Recent Developments
- 8.7 Eli Lilly
- 8.7.1 Eli Lilly Comapny Information
- 8.7.2 Eli Lilly Business Overview
- 8.7.3 Eli Lilly Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
- 8.7.5 Eli Lilly Recent Developments
- 8.8 AstraZeneca
- 8.8.1 AstraZeneca Comapny Information
- 8.8.2 AstraZeneca Business Overview
- 8.8.3 AstraZeneca Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
- 8.8.5 AstraZeneca Recent Developments
- 8.9 Xbrane Biopharma
- 8.9.1 Xbrane Biopharma Comapny Information
- 8.9.2 Xbrane Biopharma Business Overview
- 8.9.3 Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
- 8.9.5 Xbrane Biopharma Recent Developments
- 8.10 Taiwan Liposome Company (TLC)
- 8.10.1 Taiwan Liposome Company (TLC) Comapny Information
- 8.10.2 Taiwan Liposome Company (TLC) Business Overview
- 8.10.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
- 8.10.5 Taiwan Liposome Company (TLC) Recent Developments
- 8.11 Recipharm AB
- 8.11.1 Recipharm AB Comapny Information
- 8.11.2 Recipharm AB Business Overview
- 8.11.3 Recipharm AB Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
- 8.11.5 Recipharm AB Recent Developments
- 8.12 PhaseBio Pharmaceuticals
- 8.12.1 PhaseBio Pharmaceuticals Comapny Information
- 8.12.2 PhaseBio Pharmaceuticals Business Overview
- 8.12.3 PhaseBio Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
- 8.12.5 PhaseBio Pharmaceuticals Recent Developments
- 8.13 Pacira
- 8.13.1 Pacira Comapny Information
- 8.13.2 Pacira Business Overview
- 8.13.3 Pacira Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.13.4 Pacira Sustained Release Injectables Product Portfolio
- 8.13.5 Pacira Recent Developments
- 8.14 OctoPlus
- 8.14.1 OctoPlus Comapny Information
- 8.14.2 OctoPlus Business Overview
- 8.14.3 OctoPlus Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.14.4 OctoPlus Sustained Release Injectables Product Portfolio
- 8.14.5 OctoPlus Recent Developments
- 8.15 Oakwood Laboratories/PharmaSophia
- 8.15.1 Oakwood Laboratories/PharmaSophia Comapny Information
- 8.15.2 Oakwood Laboratories/PharmaSophia Business Overview
- 8.15.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
- 8.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
- 8.16 NanOlogy
- 8.16.1 NanOlogy Comapny Information
- 8.16.2 NanOlogy Business Overview
- 8.16.3 NanOlogy Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.16.4 NanOlogy Sustained Release Injectables Product Portfolio
- 8.16.5 NanOlogy Recent Developments
- 8.17 Janssen
- 8.17.1 Janssen Comapny Information
- 8.17.2 Janssen Business Overview
- 8.17.3 Janssen Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.17.4 Janssen Sustained Release Injectables Product Portfolio
- 8.17.5 Janssen Recent Developments
- 8.18 Ipsen
- 8.18.1 Ipsen Comapny Information
- 8.18.2 Ipsen Business Overview
- 8.18.3 Ipsen Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.18.4 Ipsen Sustained Release Injectables Product Portfolio
- 8.18.5 Ipsen Recent Developments
- 8.19 InnoCore Pharmaceuticals
- 8.19.1 InnoCore Pharmaceuticals Comapny Information
- 8.19.2 InnoCore Pharmaceuticals Business Overview
- 8.19.3 InnoCore Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
- 8.19.5 InnoCore Pharmaceuticals Recent Developments
- 8.20 Enzon
- 8.20.1 Enzon Comapny Information
- 8.20.2 Enzon Business Overview
- 8.20.3 Enzon Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.20.4 Enzon Sustained Release Injectables Product Portfolio
- 8.20.5 Enzon Recent Developments
- 8.21 Durect
- 8.21.1 Durect Comapny Information
- 8.21.2 Durect Business Overview
- 8.21.3 Durect Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.21.4 Durect Sustained Release Injectables Product Portfolio
- 8.21.5 Durect Recent Developments
- 8.22 Critical Pharmaceuticals
- 8.22.1 Critical Pharmaceuticals Comapny Information
- 8.22.2 Critical Pharmaceuticals Business Overview
- 8.22.3 Critical Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
- 8.22.5 Critical Pharmaceuticals Recent Developments
- 8.23 Camurus
- 8.23.1 Camurus Comapny Information
- 8.23.2 Camurus Business Overview
- 8.23.3 Camurus Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.23.4 Camurus Sustained Release Injectables Product Portfolio
- 8.23.5 Camurus Recent Developments
- 8.24 Biomarin
- 8.24.1 Biomarin Comapny Information
- 8.24.2 Biomarin Business Overview
- 8.24.3 Biomarin Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.24.4 Biomarin Sustained Release Injectables Product Portfolio
- 8.24.5 Biomarin Recent Developments
- 8.25 Avadel
- 8.25.1 Avadel Comapny Information
- 8.25.2 Avadel Business Overview
- 8.25.3 Avadel Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.25.4 Avadel Sustained Release Injectables Product Portfolio
- 8.25.5 Avadel Recent Developments
- 8.26 Aurobindo
- 8.26.1 Aurobindo Comapny Information
- 8.26.2 Aurobindo Business Overview
- 8.26.3 Aurobindo Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.26.4 Aurobindo Sustained Release Injectables Product Portfolio
- 8.26.5 Aurobindo Recent Developments
- 8.27 Ascendis Pharma
- 8.27.1 Ascendis Pharma Comapny Information
- 8.27.2 Ascendis Pharma Business Overview
- 8.27.3 Ascendis Pharma Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
- 8.27.5 Ascendis Pharma Recent Developments
- 8.28 AntriaBio
- 8.28.1 AntriaBio Comapny Information
- 8.28.2 AntriaBio Business Overview
- 8.28.3 AntriaBio Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.28.4 AntriaBio Sustained Release Injectables Product Portfolio
- 8.28.5 AntriaBio Recent Developments
- 8.29 Amylin Pharmaceuticals
- 8.29.1 Amylin Pharmaceuticals Comapny Information
- 8.29.2 Amylin Pharmaceuticals Business Overview
- 8.29.3 Amylin Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
- 8.29.5 Amylin Pharmaceuticals Recent Developments
- 8.30 Alkermes
- 8.30.1 Alkermes Comapny Information
- 8.30.2 Alkermes Business Overview
- 8.30.3 Alkermes Sustained Release Injectables Revenue and Gross Margin (2020-2025)
- 8.30.4 Alkermes Sustained Release Injectables Product Portfolio
- 8.30.5 Alkermes Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


